Apellis appoints Adam Townsend as Chief Operating Officer, effective immediately

Apellis Pharmaceuticals, Inc.

Adam Townsend, 47, previously Chief Commercial Officer since Nov 2018, assumes additional COO role.
Townsend's background includes senior leadership roles at Biogen, including SVP of Corporate Development.
No family relationships with directors or executive officers, and no reportable transactions.
Appointment effective January 16, 2024, by the Board of Directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Adam Townsend

Chief Operating Officer

APLS · Apellis Pharmaceuticals, Inc.

Effective: 2024-01-16
Filed: January 22, 2024, 6:59 PM ET

On January 16, 2024, the Board of Directors of Apellis Pharmaceuticals, Inc. (the “Company”) appointed Adam Townsend, the Company’s Chief Commercial Officer, to serve as the Company’s Chief Operating Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Townsend was appointed as Chief Operating Officer at Apellis Pharmaceuticals, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On January 16, 2024, the Board of Directors of Apellis Pharmaceuticals, Inc. (the “Company”) appointed Adam Townsend, the Company’s Chief Commercial Officer, to serve as the Company’s Chief Operating Officer, effective immediately.

View on SEC.gov

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-011699

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.